# Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

> **NCT01227902** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 203 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Retigabine IR

## Key facts

- **NCT ID:** NCT01227902
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227902, "Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01227902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*